Madrigal Pharmaceuticals Posts $212.8M Q2 Sales, 23,000 Patients on Rezdiffra, $802M Cash, New Patent to 2045

Madrigal Pharmaceuticals reported strong financial results for the second quarter of 2025, with net sales of its liver disease drug Rezdiffra (resmetirom) reaching $212.8 million, surpassing estimates of $162 million. As of June 30, 2025, more than 23,000 patients were using Rezdiffra. The company ended the quarter with $802 million in cash and cash equivalents. Earnings per share were a loss of $1.90, better than the expected loss of $3.55. Madrigal also secured a new U.S. patent for Rezdiffra, extending protection through February 4, 2045. CEO Bill Sibold highlighted the company’s positioning for decades of growth and emphasized a recent partnership to combine an oral GLP-1 drug with Rezdiffra. Analysts and investors noted the strong commercial launch of Rezdiffra and suggested Madrigal as a potential acquisition target for larger pharmaceutical companies such as Eli Lilly.